Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 384 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Standard Care Control Clear all
Withdrawn Phase 2 Interventional

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

NCT07349771
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography, Cyclophosphamide, Magnetic Resonance Imaging, Mycophenolate Mofetil, Placebo Administration, Positron Emission Tomography, Skin Biopsy, Tacrolimus, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 10, 2026, 6:34 PM EDT
Recruiting Phase 3 Interventional

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

NCT07332481
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
Interventions
Enpatoran, Placebo, Standard of care (SoC)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Los Angeles, California • Thousand Oaks, California • Cooper City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 10, 2026, 6:34 PM EDT
Terminated Phase 3 Interventional Results available

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

NCT02312206
View directory record Official record
Conditions
Primary Systemic (AL) Amyloidosis
Interventions
NEOD001, Placebo
Drug · Other
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
32
States / cities
Scottsdale, Arizona • Duarte, California • Stanford, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 10, 2026, 6:34 PM EDT
Active, not recruiting Not applicable Interventional

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

NCT05069558
View directory record Official record
Conditions
Stroke, Patent Foramen Ovale, PFO
Interventions
Investigational PFO Closure Device, Standard of Care PFO Closure Device
Device
Lead sponsor
Occlutech International AB
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
27
States / cities
Phoenix, Arizona • Stanford, California • Thousand Oaks, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 10, 2026, 6:34 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

NCT00658086
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALN-RSV01, normal saline
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 10, 2026, 6:34 PM EDT
Terminated Not applicable Interventional

PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.

NCT03502824
View directory record Official record
Conditions
Chronic Pressure Ulcers
Interventions
PuraPly® Antimicrobial Wound Matrix, SOC for Pressure Ulcers
Device · Other
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Lake Success, New York • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 10, 2026, 6:34 PM EDT
Recruiting Not applicable Interventional

Radiosurgery Treatment for Spasticity Associated With Stroke, SCI & Cerebral Palsy

NCT06070233
View directory record Official record
Conditions
Spasticity as Sequela of Stroke, Spastic Cerebral Palsy, Spasticity, Muscle
Interventions
stereotactic radiosurgery (SRS) dorsal root rhizotomy radiomodulation, Sham
Radiation · Other
Lead sponsor
Ohio State University
Other
Eligibility
16 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Winter Park, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 10, 2026, 6:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioactive Split Thickness Skin Allograft Versus Standard of Care in the Treatment of Diabetic Foot Ulcers

NCT04040426
View directory record Official record
Conditions
Diabetic Foot, Ulcer Foot
Interventions
Human split thickness skin allograft, Additional Outer Dressing Applicaiton, Offloading, Fibracol Wound Dressing
Other
Lead sponsor
Professional Education and Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
5
States / cities
San Francisco, California • O'Fallon, Illinois • Youngstown, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 10, 2026, 6:34 PM EDT
Not listed Phase 2 Interventional

Study of VF001-DP in Patients With Chronic Venous Leg Ulcers

NCT02973893
View directory record Official record
Conditions
Ulcer, Leg Ulcer, Varicose Ulcer, Pathologic Processes, Skin Ulcer, Skin Diseases, Vascular Diseases, Cardiovascular Diseases
Interventions
Placebo, VF001-DP LD, VF001-DP HD
Biological
Lead sponsor
Factor Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Carlsbad, California • Fresno, California • Laguna Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 10, 2026, 6:34 PM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

NCT03711162
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
GLPG1690, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
40 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 10, 2026, 6:34 PM EDT
Completed Not applicable Interventional

A Clinical Investigation Evaluating Wound Closure With OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's

NCT05193929
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
OptiPulse™, Standard of Care offloading device
Device
Lead sponsor
Compedica Inc
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Vista, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 10, 2026, 6:34 PM EDT
Completed Not applicable Interventional

Integrated Versus Standard Palliative Care in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT01038271
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Standard Palliative Care Group, Integrated Palliative Care Intervention
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Sep 10, 2026, 6:34 PM EDT
Active, not recruiting Not applicable Interventional

Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC

NCT06811909
View directory record Official record
Conditions
Non-infected Venous Leg Ulcer, Venous Leg Ulcer, Venous Insufficiency, Venous Stasis, Venous Reflux
Interventions
BR-AC, Standard Care
Other
Lead sponsor
BioStem Technologies
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
Guntersville, Alabama • Castro Valley, California • Glendale, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 10, 2026, 6:34 PM EDT
Completed Phase 4 Interventional Results available

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

NCT01277601
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TDF, Peg-IFN
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 10, 2026, 6:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Randomized Controlled Trial of the Effects of Daily Skin-to-skin Contact (PRCTS2S)

NCT04368767
View directory record Official record
Conditions
Premature Baby 33 to 36 Weeks, Mother-Infant Interaction, Oxidative Stress
Interventions
Skin-to-skin
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 10, 2026, 6:34 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

NCT01206101
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 10, 2026, 6:34 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

NCT03376321
View directory record Official record
Conditions
Influenza A
Interventions
Pimodivir 600 mg, Placebo, SOC Treatment
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
13 Years to 85 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 10, 2026, 6:34 PM EDT
Completed Phase 4 Interventional

Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection

NCT03880539
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
bezlotoxumab, Vancomycin Oral
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Sep 10, 2026, 6:34 PM EDT
Withdrawn Phase 4 Interventional

Pentoxifylline in Lupus Nephritis

NCT03859570
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Pentoxifylline, Placebos
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 10, 2026, 6:34 PM EDT
Completed Phase 2 Interventional

To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

NCT06264310
View directory record Official record
Conditions
Heart Failure, Worsening Heart Failure (WHF)
Interventions
Placebo, R2R01
Drug
Lead sponsor
River 2 Renal Corp.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
8
States / cities
Fairhope, Alabama • Fort Meyers, Florida • Hialeah, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 10, 2026, 6:34 PM EDT
Completed Phase 3 Interventional Results available

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

NCT02149108
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Nintedanib (BIBF 1120), Placebo, BSC
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Los Angeles, California • New Haven, Connecticut • Plainville, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 10, 2026, 6:34 PM EDT
Recruiting Not applicable Interventional

Comparing Ultrasound-Guided Transgluteal Nerve Block to Standard Care

NCT07397117
View directory record Official record
Conditions
Sciatica Acute
Interventions
nerve block with ropivacaine, Standard medical treatment
Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 10, 2026, 6:34 PM EDT
Recruiting Phase 2 Interventional

A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.

NCT06283979
View directory record Official record
Conditions
Pressure Ulcer, Stage IV, Osteomyelitis
Interventions
STIMULAN VG, Standard of Care
Combination Product · Procedure
Lead sponsor
Biocomposites Ltd
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Phoenix, Arizona • Chicago, Illinois • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 10, 2026, 6:34 PM EDT
Not listed Not applicable Interventional

A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care

NCT02487888
View directory record Official record
Conditions
Pain, Chronic Pain, Mental Disorders, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Arthritis
Interventions
Unblinded to Genetic Testing Results, Blinded to Genetic Testing Results
Other
Lead sponsor
Proove Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
31
States / cities
Beverly Hills, California • Fresno, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Sep 10, 2026, 6:34 PM EDT